Effective antihypertensive therapy: Blood pressure control with moxonidine

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 3, 1996, Pages

  Prichard, B N C ^a   Graham, B R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hypertension treatment comparisons; Moxonidine; Pharmacodynamics; Pharmacokenetics

Indexed keywords

ADRENALIN; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; MOXONIDINE; NIFEDIPINE; NORADRENALIN; RENIN;

ADULT; AGED; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MALE; META ANALYSIS; PRIORITY JOURNAL; SYMPATHETIC BLOCKING; SYSTOLIC BLOOD PRESSURE;

EID: 0029788114     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199627003-00006     Document Type: Conference Paper

References (40)

1. Chrisp P, Faulds D. Moxonidine: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1992;44:993-1012.
2. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992;20(suppl 4):S1-10.
3. Prichard BNC. Principles and practice of α-anti-adrenergic therapy in cardiovascular drug therapy. In: Messerli FH, ed. Philadelphia: WB Saunders, 1990:624-40.
4. Weimann HJ, Rudolph M. Clinical pharmacokinetics of moxonidine. J Cardiovasc Pharmacol 1992;20(suppl 4):S37-41.
5. Mitrovic V, Patyna W, Hüting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991;5: 967-72.
6. Kirch H, Hutt H-J, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990;30: 1088-95.
7. Kirch H, Hutt H-J, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988;15:245-53.
8. Klink F. Clinical investigation of the passage of moxonidine from the maternal bloodstream to the breast milk in patients with hypertension. Beiersdorf AG Study No. 200 029-5895-2228-52, 1990.
9. MacPhee GJA, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992;33:261-7.
10. Mitrovic V, Patyna WD, Yahya H, Schlepper M. Einfluss des Imidazolin-rezeptoragonisten Moxonidin auf die zentrale und periphere Hämodynamik bei Patienten mil essentieller Hypertonie. Interlaken: Joint Meeting Swiss and German Society of Cardiology, April, 1994.
11. Hüting J, Mitrovic V, Bahavar H, Schlepper M. Vergleich der Wirkungen von Moxonidin und Nifedipin auf die links-ventrikuläre Funktion bei Monotherapie der essentiellen Hypertonie. Herz Kreislauf 1992;24:132-7.
12. Eichstädt H, Richter W, Bäder W, et al. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989;3:583-7.
13. Eichstädt H, Gatz G, Schröder R, Kreuz D. Linksventrikuläre Hypertrophieregression unter einer Therapie mit Moxonidin. J Pharmacol Ther 1991;1:12-7.
14. Schmidt U, Frederick H, Kraft K, Schenk N, Löw-Kröger A. Hypertension: a possible risk in road traffic. J Cardiovasc Pharmacol 1992;20(suppl 4):S50-6.
15. DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web. J Cardiovasc Pharmacol 1992;20(suppl 11):S1-16.
16. Prichard BNC, Smith CCT, Sen S, Betteridge DJ. Hypertension and insulin resistance. J Cardiovasc Pharmacol 1992;20(suppl 11):S77-84.
17. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG. Ziegler D. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995;5(suppl 1): 19-27.
18. 2-adrenergic agonist moxonidine on anterior pituitary hormone secretion in comparison to clonidine and GHRH. Acta Endocrinol 1989;120(suppl 1):80-4.
19. 2-adrenoreceptor agonist in arterial essential hypertension. Clinical experience with moxonidine. Curr Ther Res 1987; 42:138-46.
20. Plänitz V, Kandziora J. Wirksamkeit und Verträglichkeit des neuen Antihypertensivums Moxonidin bei vorwiegend älteren Patienten. Therapeiwoche 1984;34:6426.
21. Schwartz VW, Kandziora J. Langzeiterfahrungen mit Moxonidin, einem neuen Antihypertensivum. Fortschr Medizin 1990;108:64-70.
22. 1 receptor agonist moxonidine in patients with mild to moderate essential hypertension. Eur J Clin Res 1995;7:227-40.
23. Frei M, Küster L, Gardosch von Krosigk P-P, Kock H-F, Küppers H. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994;24:525-8.
24. Larrat V. Efficacy and tolerance of moxonidine in comparison with a standard therapy with hydrochlorothiazide. Beiersdorf AG Report No. 200.029-28-54, 1990.
25. Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987; 27:46-51.
26. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992;20(suppl 4):S42-4.
27. Mangiameli S, Privitera A, Jonte G, Löw-Kröger A. Behandlung der leichten bis mittelschweren Hypertonie. Moxonidine versus Nifedipine Retard. Zeit Allgemeinmed 1991;68: 862-6.
28. Lotti G, Gianrossi R. Moxonidin versus Captopril bei leichter bis mittelschwerer Hypertonie. Fortschr Medizin 1993; 111:429.
29. Ollivier JP, Christen MO, Schäfer SG. Moxonidine: a second generation of centrally acting drugs. An appraisal of clinical experience. J Cardiovasc Pharmacol 1992;20(suppl 4):S31-7.
30. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994;24:529-33.
31. Küppers H, Jäger BA, Luscik J, Gräve M, Hughes P, Kaan EC. Placebo- and enalapril-controlled evaluation of the efficacy and tolerability of once-daily moxonidine in mild to moderate essential hypertension. [In preparation.]
32. Plänitz V. Intra-individuul comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986;29:645-50.
33. Prichard BNC, Simmons R, Rooks MJ, Haworth DA, Laws D, Wonnacott S. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992;20 (suppl 4):545-9.
34. Kaan EC, Jäger BA, Verbcom C, Prichard BNC. An analysis of the spectrum of activity of moxonidine. [In preparation.]
35. Mitrovic V. Haemodynamic effects of moxonidine in patients with congestive heart failure during the first three hours after administration of a single 0.4 mg dose. Eur J Clin Res 1996 (in press).
36. Wilkens H, Wilkens JH, Fabel H. Die Wirkung von Moxonidin - einem zentral wirksamen Antihypertensivum - auf Atemregulation und Histaminreaktivität. Kardio 1992;10: 1-4.
37. 2-Adrenozeptor-Agonisten bei Patienten mit arterieller Hypertonie. Cor Vasc 5(Pt 3): 1-12.
38. Ongyert D, Dotzer F. Wirksamkeit und Verträglichkeit von Moxonidin. Zeit Allgemeinmed 1993;69:856-60.
39. Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984;27:147-52.
40. Webster J, Koch HF. Rebound and aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996;27(suppl 3):S49-54 (this issue).